Hepatic steatosis is an underlying feature of nonalcoholic fatty liver disease (NAFLD), which
is the most common form of liver disease and is present in up to∼ 70% of individuals who …

Abstract Background and Aim: The magnitude of the risk of incident type 2 diabetes (T2D)
and metabolic syndrome (MetS) among patients with nonalcoholic fatty liver disease …

Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2DM) are common
conditions that regularly co-exist and can act synergistically to drive adverse outcomes. The …

Background Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver
disease worldwide. It affects an estimated 20% of the general population, based on cohort …

The number of individuals with prediabetes is expected to grow substantially and estimated
to globally affect 482 million people by 2040. Therefore, effective methods for diagnosing …

Abstract Non‐alcoholic steatohepatitis (NASH), the progressive form of non‐alcoholic fatty
liver disease (NAFLD), is emerging as a main health problem in industrialized countries …

Non Alcoholic Fatty Liver Disease (NAFLD), defined as the presence of a significant amount
of lipid accumulation in the liver (at least in 5% of hepatocytes), represents a challenging …

Importance Nonalcoholic fatty liver disease (NAFLD) is a common condition that is most
often asymptomatic. It is associated with metabolic syndrome, incident diabetes, carotid …

Nonalcoholic fatty liver disease (NAFLD) is the liver manifestation of the complex metabolic
derangements associated with obesity. NAFLD is characterized by excessive deposition of …

Abstract Aims Trimethylamine N-oxide (TMAO), choline and betaine serum levels have been
associated with metabolic diseases including type 2 diabetes (T2D) and non-alcoholic fatty …